Thomas D Schmittgen

Thomas D Schmittgen, Ph.D.

CHAIR & PROF

Department: Pharmaceutics
Business Phone: (352) 273-8028
Business Email: tschmittgen@cop.ufl.edu

About Thomas D Schmittgen

Thomas D. Schmittgen, Ph.D. is a professor and Chair in the Department of Pharmaceutics at the University of Florida in Gainesville and is the V. Ravi Chandran Professor of Pharmaceutical Sciences. Dr. Schmittgen holds both undergraduate (Pharmacy) and graduate degrees (Pharmaceutics) from the Ohio State University. He was a National Research Service Award (NIH) postdoctoral fellow at the University of Southern California from 1992-1995. He served on the faculty at Washington State University College of Pharmacy from 1995-2002. Dr. Schmittgen returned to the Ohio State University in 2002 where he remained on the faculty for 13 years, serving as chair of the Division of Pharmaceutics from 2000-2015. Dr. Schmittgen was hired at the University of Florida in 2015 through the UF Preeminence Initiative.

Accomplishments

Best basic science paper
2017 · University of Florida
Fellow
2016 · American Association of Pharmaceutical Scientists
Co-author of the 21st most cited scientific paper of all time
2014 · Reported in Nature, Oct. 2014
Inventor of the year
2011 · TechColumbus Innovation Awards
Individual National Research Service Award
1993-1995 · National Institutes of Health
Fellow
1990-1991 · Berlex

Research Profile

Dr. Schmittgen’s research focuses on noncoding RNAs and cancer with emphasis on the use of microRNAs as therapeutic or diagnostic agents. A paper he co-authored in 2001 describing the relative method of gene quantification has been cited over 105,000 times and was ranked in 2014 by the international journal Nature as the 21st most cited scientific article of all time. Dr. Schmittgen has been continuously funded by federal agencies (NIH, DOD) for the past 20 years. His lab was the first to establish a link between altered microRNA expression in pancreatic cancer. Dr. Schmittgen’s lab is currently developing exosomes/microvesicles as targeted drug delivery systems for the treatment of cancer. Dr. Schmittgen is a member of the American Association for Cancer Research, American Association for the Advancement of Science and is a Fellow of the American Association of Pharmaceutical Scientists.

Areas of Interest
  • Cancer
  • Drug delivery
  • Drug development
  • Exosomes
  • Extracellular vesicles
  • MircroRNA
  • RNA
  • Therapeutics

Publications

2018 International journal of molecular sciences
2017 Biochemical and biophysical research communications
2014 Journal of visualized experiments : JoVE
2013 HPB : the official journal of the International Hepato Pancreato Biliary Association
2011 Pharmaceutical research
2010 Future oncology (London, England)
2010 Diagnostic molecular pathology : the American journal of surgical pathology, part B
2009 American journal of respiratory and critical care medicine
2008 Diagnostic molecular pathology : the American journal of surgical pathology, part B
2008 Clinical cancer research : an official journal of the American Association for Cancer Research
2008 Methods (San Diego, Calif.)
2008 Molecular cancer therapeutics
2008 International journal of cancer
2008 Biochemical and biophysical research communications
2008 Methods in molecular biology (Clifton, N.J.)
2001 Methods (San Diego, Calif.)
2000 Toxicological sciences : an official journal of the Society of Toxicology

Grants

Jul 2020 ACTIVE
OR-DRPD-ROF2020: Evaluating exosome heterogeneity by single vesicle sequencing
UF RESEARCH · Principal Investigator
Sep 2019 ACTIVE
Novel Targeted Anticancer Agents from Marine Cyanobacteria
NATL INST OF HLTH NCI ·
May 2019 – Jul 2019
Organize 12th Symposium on New Development in Clinical Pharmacy and Clinical Pharmacology
BOEHRINGER INGELHEIM PHARM INC · Principal Investigator
Sep 2018 ACTIVE
2/3 Florida-California Cancer Research, Education & Engagement (CaRE2) Health Equity Center
NATL INST OF HLTH NCI · Project Manager
Dec 2017 – Dec 2018
Pfizer Agreement for Graduate Student Support
PFIZER INC · Principal Investigator
Aug 2017 – Dec 2019
The Novel Role of REST in the Development of Pancreatic Ductal Adenocarcinoma
NATL INST OF HLTH NCI ·
Aug 2015 – Jul 2019
Targeted delivery of microRNA-loaded microvesicle for cancer therapy
NATL INST OF HLTH NCATS · Principal Investigator
Dec 2004 ACTIVE
Pfizer Graduate Fellowship Award
PFIZER INC · Principal Investigator

Education

Post Doc – Biochemistry & Molecular Biology
1995 · University of Southern California
Ph.D. – Pharmaceutics
1992 · Ohio State University
B.S. – Pharmacy
1985 · Ohio State University

Contact Details

Phones:
Business:
(352) 273-8028
Emails: